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ABSTRACT
Diacylglycerol kinase (DGK)α converts diacylglycerol to phosphatidic acid. This 
lipid kinase sustains survival, migration and invasion of tumor cells, with no effect over 
untransformed cells, suggesting its potential as a cancer-specific target. Nonetheless 
the mechanisms that underlie DGKα specific contribution to cancer survival have 
not been elucidated. Using three-dimensional (3D) colon and breast cancer cell 
cultures, we demonstrate that DGKα upregulation is part of the transcriptional 
program that results in Src activation in these culture conditions. Pharmacological 
or genetic DGKα silencing impaired tumor growth in vivo confirming its function in 
malignant transformation. DGKα-mediated Src regulation contributed to limit the 
effect of Src inhibitors, and its transcriptional upregulation in response to PI3K/Akt 
inhibitors resulted in reduced toxicity. Src oncogenic properties and contribution to 
pharmacological resistance have been linked to its overactivation in cancer. DGKα 
participation in this central node helps to explain why its pharmacological inhibition 
or siRNA-mediated targeting specifically alters tumor viability with no effect on 
untransformed cells. Our results identify DGKα-mediated stabilization of Src activation 
as an important mechanism in tumor growth, and suggest that targeting this enzyme, 
alone or in combination with other inhibitors in wide clinical use, could constitute a 
treatment strategy for aggressive forms of cancer.
INTRODUCTION
The diacylglycerol kinases (DGK) phosphorylate 
diacylglycerol (DAG) to produce phosphatidic acid (PA); 
DGK thus regulate the levels of two lipids with key roles 
in signaling and metabolic pathways [1]. Many reports 
support a positive role for the DGKα isoform in cancer 
progression. This lipid kinase assists tumor survival [2-
4], migration and invasion [5-7]. DGKα expression is 
increased in tumors compared to adjacent non-cancerous 
tissue [3, 4], as well as in metastasis of the original tumor 
[8, 9]. When mutated, it is a causative gene in pancreatic 
cancer [10], and was recently described as a potential 
target for glioblastoma treatment [11]. Nonetheless, 
the mechanisms by which DGKα contributes to these 
processes, and the exact tumor context for which DGKα 
is an effective target have not been elucidated.
DGKα function is regulated by transcriptional and 
post-transcriptional mechanisms. Distinct routes converge 
and are integrated at the DGKα gene promoter region, 
including those of PI3K/Akt/FoxO, p53 and Ras [12-14]. 
DGKα is a cytosolic enzyme, and its phosphorylation by 
distinct members of the Src family kinases (SFK) lead to 
its recruitment to the plasma membrane and activation 
[15-18]. SFK are non-receptor tyrosine kinases that 
share a common modular structure including a SH3 and 
a SH2 domains involved in protein interactions, and 
a myristoylation site at the N-terminus for membrane 
targeting [19]. In vitro experiments with GST (glutathione 
S-transferase)-purified DGKα and recombinant Src 
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mapped DGKα interactions with Src SH2 and SH3 regions 
[18].
Src is the most widely expressed member of the 
SFK family and is relevant in many cancer types, since it 
controls tumor cell proliferation, survival, migration and 
invasion [20, 21]. Src regulates mitogenic and survival 
signaling cascades downstream of receptors tyrosine 
kinase (RTK), which are frequently mutated and/or 
overexpressed in breast and colon cancer. Oncogenic Src 
functions are also related to its activation downstream 
of integrins to regulate survival and invasion [22]. Src 
activity is predictive of poor clinical prognosis in colon 
and pancreatic cancer [23, 24]. These findings have led 
to substantial efforts to test the therapeutic potential 
of Src inhibitors in advanced cancers such as breast 
and colon, which are very frequent tumor types and 
tend to present early relapse and metastasis. Although 
preclinical evidence supported the use of such inhibitors, 
its therapeutic effectiveness as single agents in clinical 
assays for solid tumors has been discouraging [25]. This is 
probably due to incomplete knowledge of the mechanisms 
that control Src transforming potential and of the cancer-
related Src-regulated pathways. Src is involved in many 
fundamental cellular processes, but the Src deficient mice 
are viable [26]. In contrast to viral oncoproteins, Src alone 
is insufficient to transform cells in vitro, and activating 
mutations of SFK are rarely observed in cancer [27, 28], 
suggesting further control by specific Src regulators that 
promote or restrain its tumorigenic properties [29, 30].
Here we tested the hypothesis that DGKα expression 
in tumor cells contributes to oncogenic SFK functions. 
We analyzed the DGKα contribution to breast and colon 
cancer in 3D cell cultures. These culture conditions closely 
mimic the in vivo cell environment and have been used 
to demonstrate the activation of transcription programs 
that lead to tumor survival and drug resistance [31-33]. 
Tumor cell growth in 3D culture is particularly dependent 
on integrin and Src signaling cascades, a property that it is 
not recapitulated in 2D conditions nor in non-transformed 
cells [34]. We found that DGKα silencing or inhibition 
prevented cancer cell growth in 3D culture as well as 
tumor growth in vivo. Analysis of DGKα expression and 
Src activation under 3D conditions provided a mechanistic 
link by showing that DGKα expression has a positive 
regulatory function in Src activation. DGKα contribution 
to this central node helps to explain why targeting of 
DGKα specifically alters tumor viability, with no effect 
on untransformed cell survival. We identified DGKα as 
a Src-interacting partner that is necessary to sustain Src 
signaling and whose targeting improved the effect of Src 
and PI3K/Akt inhibitors. Our findings indicate that DGKα 
might be an effective target for anti-cancer therapies, alone 
or in combination with other widely used inhibitors.
RESULTS
DGKα is necessary for cancer cell growth in 3D 
culture
DGKα has been studied in several cancer models, 
where experimental evidence has shown that it mediates 
various aspects of cancer cell progression. No studies have 
addressed the contribution of this isoform to colon cancer 
so we selected the SW480 cell line, which was derived 
from a primary colorectal tumor and shows characteristics 
of highly transformed cells. The contribution of DGKα to 
the tumoral properties of SW480 cells was addressed by 
reducing its expression using interferent RNA. Previous 
validated DGKα target sequence [35, 36] efficiently 
reduced the expression of the protein in SW480 cells 
(Fig. S1A). Expression of DGKζ, an isoform that 
complements some DGK functions in T lymphocytes, 
was not altered in DGKα silenced cells (Fig. S1A). To 
evaluate the contribution of DGKα during long-term 
culture, the targeting sequence was cloned as shRNA in 
the pSuperRetro vector; this was then used to generate 
cells with stable reduction of DGKα levels (Fig. S1B). 
The effect of DGKα downmodulation on long-
term growth of SW480 cells was evaluated in matrigel 
3D culture and on plastic, 2D culture conditions. In 3D 
culture, SW480 cells showed a disorganized structure 
with poor cell-cell contacts, characteristic of highly 
transformed tumors [37]. Reduced DGKα expression in 
3D cultures of the stably downregulated SW480 cells was 
corroborated by immunofluorescence (Fig. 1A). When 
compared to their control counterpart, cells with reduced 
DGKα levels formed smaller colonies (Fig. 1B). DGKα 
attenuation impaired cell proliferation, as revealed the 
reduced number of cells incorporating EdU (5-ethynyl-2 
deoxyuridine), a thymidine analogue that measures DNA 
synthesis (Fig 1C).
Reduction of DGKα protein levels did not 
significantly affect cell growth in 2D; these cells formed 
colonies at the same extent that control cells (Fig. S2A). 
The effect of reduced DGKα expression on cell growth in 
either 2D or 3D conditions was compared by measuring 
cell viability with a tetrazolium reduction based assay 
(MTS). Simultaneous MTS measurements confirmed that 
DGKα silencing affected the viability of SW480 cells only 
when in 3D (Fig. S2B). These observations indicate that 
DGKα, whereas dispensable for 2D cell growth, is central 
for sustaining cancer cell growth in a 3D context.
Cancer cell growth in 3D induces tumorigenic traits 
that cells display in vivo and are not recapitulated in 2D 
culture. The contribution of DGKα to SW480 growth 
in 3D suggests that this enzyme could be of interest for 
cancer therapy. To study the potential of this pathway as a 
target for pharmacological intervention, we next compared 
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the effect of diminishing DGKα protein levels with that 
produced by a pharmacological inhibitor. We selected 
the DGK inhibitor II (R59949) that binds to and blocks 
DGKα catalytic functions [38]. R59949 is reported to 
be more efficient that the other DGK inhibitor (R59022) 
in blocking the Ca2+-dependent type I DGK isoforms in 
vitro, mainly DGKα. R59949 inhibits purified DGKα in 
the low micromolar range [38], but it is highly lipophilic 
and tends to be sequestered by serum lipids when added to 
cell cultures [39]. By this reason the drug is used in serum-
free culture conditions or, if serum is present, higher 
concentrations must be used. In this case R59949 may 
also inhibit other DGK isoforms [40]. 3D assays required 
long-term cell culture in serum-supplemented media so we 
first assessed the expression of additional DGK isoforms 
in SW480 cells.
Data from our related studies indicated that in 
addition to DGKα, SW480 cells also expressed DGKζ 
(Fig. S1B). Due to the lack of efficient commercial anti-
DGK antibodies, we tested the expression of the remaining 
Figure 1: DGKα is necessary for cancer cell growth in 3D conditions. (A) Stably control or DGKα-depleted SW480 cells were 
seeded on matrigel and cultured for 6 days. Cells were stained for DGKα and with DAPI. (B) Colony area (a) from control and DGKα-
depleted cells was determined using the ImageJ software, and expressed in arbitrary units (a.u.). The mean ± SEM of the area of each group 
is shown (top). The area value was classified in 3 categories (a>5, 5>a>1, a<1 a. u.), the area distribution is showed for each group (bottom). 
n=50 colonies in each case. (C) Cell nuclei were stained with DAPI and proliferation inferred by staining with EdU. % EdU positive cells 
(mean ± SEM) in the total of DAPI stained cells was determined in several fields of at least 3 different experiments. (D) SW480 and MDA-
MB-468 cells were seeded on matrigel (4 days) and R59949-treated (48 h). Cells were stained and analyzed as in C. (E) Caco-2 and MCF-
10A cells were seeded on matrigel (4 days), R59949-treated (48 h), and stained for actin and with DAPI. A representative field is shown (n 
≥3 independent experiments). A, C, D, bar = 50 µm; B, bar = 25 µm.
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DGK isoforms by RT-PCR. This analysis indicated that 
SW480 cells also expressed type II DGKδ and DGKη, and 
type III DGKε; but not type IV DGKι or type V DGKθ 
(Fig. S3A). To discard that in our experimental conditions, 
R59949 could inhibit not only DGKα, but also some of 
the other expressed DGK, we determined the efficiency 
and selectivity of R59949 by comparing its effects over 
total DGK activity in control and DGKα silenced cells. 
We have previously used 30 µM of the inhibitor to 
demonstrate the DGKα-mediated control of hypoxia-
inducible factor-1α; this same dose has been reported by 
other groups to confirm DGK function [41-43]. We thus 
cultured SW480 cells for 24 h in complete medium in the 
presence of R59949 at 15 and 30 µM. The lower dose had 
a minimum effect over total DGK activity, whereas 30 µM 
R59949 diminished DGK activity by near 25%. A similar 
reduction was observed in cells with DGKα silencing, and 
in this case R59949 addition did not further affect activity 
(Fig. S3B).
We next investigated if the R59949-resistant 
DGK activity in SW480 cells could be ascribed to the 
DGKζ isoform that, as we have previously shown, has 
a prominent role in controlling total DGK activity in T 
cells [36, 44]. We found that DGKζ contribution was 
also important in SW480 cells, since its targeting led to a 
severe reduction in total DGK activity (Fig. S3B). R59949 
addition to DGKζ-silenced cells fully abolished DGK 
activity, confirming the drug sensitivity of the remaining 
isoforms, most probably DGKα, in these cells. This agrees 
with previous reports indicating the high sensitivity of 
DGKα to R59949 [38, 40], and further indicates that this 
isoform is the main target of R59949 in these cells. 
The effect of pharmacological DGK inhibition was 
next assessed using SW480 cells growing in 3D. As for 
DGKα depletion, R59949 treatment of matrigel-plated 
SW480 cells reduced colony formation (Fig 1D, upper 
panel). Results were similar for the breast cancer cell 
line MDA-MB-468, which showed spheroid-like growth 
with grape-like morphology [37] (Fig. 1D, lower panels). 
Quantification of EdU incorporation confirmed that, 
as shown for DGKα silenced cells, R59949 treatment 
diminished proliferation in the two cell lines (Fig. 1D).
Different from these two highly transformed cells, 
some cell lines form well-organized acinar-like structures 
that resemble normal epithelia when cultured under 3D 
conditions [37]. To be appropriate for clinical use, DGKα 
inhibition should have little or no effect on untransformed 
cell growth. We next tested the effect of DGKα inhibition 
on the Caco-2 cell line that, although it is classified as 
colon cancer, forms acinar-like structures in matrigel 
culture and is widely used to study colon morphogenesis 
[45]. R59949-induced DGKα inhibition did not affect the 
acinar-like morphology of these cells that grew at the same 
extent that vehicle-treated cells (Fig. 1E, S2C). R59949 
had no effect on the polarized growth of MCF-10A cells, 
a breast-derived cell line that forms organized structures in 
3D culture [46], Fig.1E, S2C). These data indicate that the 
disorganized growth characteristics of transformed cells 
require DGKα. 
DGKα depletion impairs tumor growth in vivo
Silencing of DGKα had no effect on cancer cell 
growth in 2D culture, at difference from that observed 
when cells were cultured in 3D. This characteristic 
suggests that DGKα sustains three-dimensional 
configuration in vitro, and thus possibly in vivo. We next 
examined the contribution of DGKα to maintain 3D 
growth in vivo, using DGKα silenced SW480 colon cancer 
cells in xenograft assay models. Mice injected with stably 
silenced DGKα SW480 cells developed tumors, but they 
appeared later and grew less compared to control cells 
(Fig. 2A). Tumors generated upon injection of DGKα 
silenced cells were smaller and weighted ~50% less than 
those of control cells (Fig. 2B, C). Western blot analysis 
of tumor lysates confirmed that DGKα silencing was 
maintained along the experiment (Fig. 2D).
To evaluate the in vivo potential of pharmacological 
DGKα targeting, we also determined the effect of the 
R59949 inhibitor on SW480 cell xenografts. Our group 
has reported that DGK inhibitors and rapamycin have 
similar effects over cell proliferation [47]. We thus chose 
a dose of 10 mg/kg of the inhibitor; similar to that used 
for rapamycin in xenograft assays [48]. In a pilot study, 
intraperitoneal (i.p.) administration of the corresponding 
volume of DMSO or R59949 in DMSO resulted highly 
toxic for the mice. We then selected an alternate vehicle 
for R59949 administration, using the drug in emulsion 
with 50% of PEG3000 in PBS. Again i.p. administration 
of PEG either alone or with R59949 was toxic at long 
term (50% mice from each group died following the 
second dose of treatment). Finally, R59949 in emulsion 
with PEG3000 was subcutaneously administrated. Mice 
were injected with SW480 cells, tumors were let to grow 
and R59949 was first injected when the tumors reached 
a volume of approximate 150 mm3. After the initial 
injection, the inhibitor was continuously injected every 48 
h during 10 days, when tumors in control animals reached 
the maximal authorized size (Fig. 2E). This treatment 
was not toxic for the animals, as assessed by the lack of 
differences in the weight of vehicle and inhibitor treated 
mice (Fig. S4). R59949-treatment resulted in marked 
reduction of tumor growth (Fig. 2F). The impairment 
in tumor growth was statistically significant when the 
volume of each individual tumor was normalized to that 
measured prior inhibitor injection (Fig. 2G). Although 
R59949 treatment did not result in tumor regression, 
tumors excised from R59949-treated mice were smaller 
and weighted less than those obtained from vehicle-
treated mice (Fig. 2H, I). Immunohistochemical analysis 
revealed reduced Akt phosphorylation and increased 
cleaved caspase 3 staining in tumors from R59949-
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Figure 2: DGKα depletion impairs tumor growth in vivo. Stably infected control or DGKα-depleted SW480 cells (1.5 x 106) 
were injected s.c. into immunosuppressed mice (n = 6 mice/group). (A) Tumor volume was recorded every 48 h. The mean ± SEM of the 
volume of each mice group is shown. (B) After sacrifice, tumors were resected. Tumors of DGKα-depleted cells showed a minor size that 
those from control cells. (C) Tumor weighed (mean ± SEM). (D) Tumors were lysed in RIPA buffer using a tissue homogenizer and DGKα 
expression was determined by western blot. Actin was used as loading control (E) Diagram showing the schedule for testing the potential 
of targeting DGKα in a xenograft assay. SW480 cells (106) were injected s.c. into immunosuppressed mice. When tumor volume reached 
∼150 mm3, mice were divided in two random groups (n = 6 mice/group) and treated s.c. with vehicle or R59949 every 48 h for 10 days. 
Tumor volume was recorded every 48 h. Mice were sacrificed at day 10 of the treatment. The volume mean (F) and the x-fold change (G) 
mean ± SEM in each case are shown. (H, I) After sacrifice the tumors were resected and weighed (mean ± SEM). (J) Tumors were fixed and 
stained with hematoxylin-eosin and for cleaved caspase 3 and AKT phosphorylated at S473. Each experiment was repeated twice.
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treated mice (Fig. 2J). This analysis strongly suggests 
that pharmacological DGKα inhibition correlated with 
impairment of survival pathways and increased apoptosis.
DGKα promotes Src activation
Our results suggested that DGKα participates in 
a central node that promotes cancer cell growth in a 3D 
context. Culture on matrigel matrices closely mimics 
the tumor microenvironment and reproduces the cell 
reprogramming that occurs in vivo. The DGKα promoter 
contains several regulatory regions that, as shown in T 
lymphocytes, modulate transcriptional expression of 
this enzyme along differentiation stages [14]. We thus 
investigated if DGKα expression varied as a result of 3D 
culture conditions. DGKα mRNA levels were ∼3-fold 
higher in 3D-cultured SW480 cells compared to 2D culture 
(Fig. 3A), suggesting 3D-mediated upregulation of DGKα 
gene expression. We found correlation between increases 
in DGKα mRNA and in the total amount of DGKα 
protein (Fig. 3B). Higher DGKα protein levels were also 
observed for breast tumor-derived cell lines in 3D cultures 
suggesting a direct correlation with 3D imposed restrains 
(Fig. S5). An increase in tyrosine signaling networks, 
specifically those of the Src family, is a characteristic of 
colon and breast cancers [49, 50], and is critical to sustain 
Figure 3: DGKα levels increase in 3D cell cultures and regulate Src signaling networks. SW480 cells were plated at 
subconfluence (2 days) or on matrigel (6 days). (A) RNA was extracted and DGKα analyzed by qPCR. Expression was normalized to that 
of GAPDH. Mean SEM, n = 3. (B) DGKα levels, active Src and phosphotyrosine profiles were analyzed by western blot. Total Src and 
actin were used as loading controls. (C) DGKα immunoprecipitates of SW480 cells were probed for Src association. An unrelated antibody 
was used as a control. (D) Active Src was evaluated in SW480 cells in exponential growth with reduced DGKα levels. Total Src and tubulin 
were used as loading controls. (E) Chicken Src and human Myc-DGKα were transiently transfected in HEK-293 cells. After 24 h, cells were 
treated for 6 h with R59949 (20 µM) or PP2 (10 µM), and Myc-DGKα immunoprecipitated to analyze its phosphorylation and association 
with Src. (F) As in E, but wild type (WT) or kinase-dead (KD) Myc-DGKα were transfected. Phosphotyrosine profiles were analyzed by 
western blot. (G) SW480 cells were transiently transfected with control, scramble RNAi or targeting DGKα. 72 h post-transfection, the 
indicated Myc-tagged DGKα constructions were transfected. DGKα levels and active Src were analyzed by western blot. Total Src and 
actin were used as loading controls. (H, I) Active Src was evaluated in SW480 cells in exponential growth treated with 30 µM R59949 (H), 
or in tumors from R59949-treated mice (I). Total Src, tubulin and actin were used as loading controls. Representative blots are shown (n ≥3 
independent experiments, except n=2 in I).
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disorganized growth under 3D conditions [51]. SW480 
cells cultured in 3D conditions also showed greater Src 
phosphorylation at Y419, an autophosphorylation site that 
correlates with optimal Src activity. The increase in Y419 
phosphorylation was accompanied by an overall increase 
in the phosphotyrosine profile (Fig. 3B).
DGKα is known to be a SFK-regulated target in 
T cells, as well as in cells of endothelial and epithelial 
origin. A recombinant GST-DGKα version interacts with 
and is phosphorylated by recombinant Src [18], and 
DGKα membrane recruitment and/or activity are induced 
by SFK-phosphorylation [16, 17]. Other Src effectors, 
through their association with Src, facilitate an open 
conformation of the kinase and thus its activation [52]. 
As increased Src activation in 3D conditions coincided 
with higher DGKα levels, with no obvious change in Src 
protein expression, we explored a possible correlation 
between DGKα upregulation and Src activation. 
Immunoprecipitation assays showed that endogenous 
DGKα associated to Src in SW480 cells (Fig. 3C). In these 
cells, DGKα silencing correlated with a notable reduction 
in Src Y419 phosphorylation, indicating Src inactivation 
(Fig. 3D). These observations suggest a mutual regulation 
between Src and DGKα where, as described for other 
SFK targets, DGKα interaction with Src facilitates Src 
activation.
To study in more detail the requirements for Src 
and DGKα interaction, we overexpressed both proteins 
in HEK293 cells, which do not express DGKα. DGKα 
was overexpressed as a Myc-tagged protein, to facilitate 
its immunoprecipitation. As observed for the endogenous 
proteins, the ectopically expressed DGKα interacted 
with Src and phosphotyrosine analysis confirmed DGKα 
phosphorylation (Fig. 3E). Treatment with the Src 
inhibitor PP2 did not disrupt DGKα−Src interaction, 
although it abolished tyrosine phosphorylation of DGKα. 
In contrast, treatment with the DGK inhibitor impaired 
DGKα−Src interaction (Fig. 3E). 
To determine if the lack of DGKα−Src interaction 
was a direct consequence of impaired DGK activity, we 
examined the interaction of Src with a kinase-deficient 
DGKα mutant. DGKα, rendered inactive by mutation 
of the conserved, ATP-binding GGDG sequence [53], 
interacted with Src and was tyrosine phosphorylated (Fig. 
3F). This indicates that DGKα enzymatic activity was 
dispensable for its interaction with Src. It also suggests 
that R59949-mediated complex disruption is probably the 
result of sterically hindrance following inhibitor binding 
to the DGKα catalytic domain. Total phosphotyrosine 
profile analysis, however, suggested increased Src activity 
in cells expressing the active DGKα construct (Fig. 3F), 
suggesting some contribution of DGKα activity for full 
Src activation.
Determination of Src activation in HEK293 cells 
was limited by the high level of ectopically expressed 
Src as well as by the expression of additional SFK 
members (see additional bands in HEK293 lysates). We 
thus reconstituted DGKα-silenced SW480 cells with 
wild type and kinase-dead DGKα versions (Fig. 3G). 
In these conditions, full Src phosphorylation was only 
reconstituted by wild type DGKα but not by the kinase-
dead mutant. This suggests that the enzymatic activity 
of DGKα is required to achieve complete activation of 
endogenous Src. R59949 treatment mimicked the effect of 
DGKα attenuation and resulted in a strong reduction of Src 
Y419 phosphorylation (Fig. 3H). Finally, the analysis of 
Src activation in tumor lysates from vehicle- and R59949-
treated mice bearing SW480 induced tumors, confirmed 
that treatment with R59949 in vivo also diminished Src 
activation (Fig. 3I).
DGKα silencing increases cancer cell sensitivity to 
Src inhibition
Despite the importance of Src in malignant 
transformation, monotherapy using Src inhibitors in 
clinical trials has had only modest results [54]. Aspects 
of the 3D tumor environment may contribute to limit 
drug effectiveness including the spatial activation of Src 
and its regulation by interacting partners. The previous 
experiments suggested that DGK inhibitor treatment 
impaired DGKα interaction with Src, so we hypothesized 
that disruption of DGKα-Src complex could not only 
diminish Src activation, but also enhance its sensitivity 
to pharmacological inhibitors. Treatment of SW480 cells 
with the Src inhibitor PP2 diminished Src phosphorylation 
similar to that observed when treating cells with the 
DGK inhibitor. The dose of PP2 required to impair Src 
phosphorylation was reduced when SW480 cells were co-
treated with the DGK inhibitor (Fig. 4A). Decreased Src 
phosphorylation correlated with diminished total tyrosine 
phosphorylation and reduced expression of Cyclin D3, a 
cell cycle promoter that is upregulated in many tumor cells 
[55]. 
The effect of drug combination was also evaluated 
in 3D cultures using cleavage caspase 3 as an indicator 
of apoptotic cell death. In these experiments PP2 was 
assayed at 10 µM, a concentration reported when using 
3D conditions to avoid diffusion and lack of effectiveness 
due to matrix structure [51]. PP2 treatment at this 
concentration partially reduced 3D growth and promoted 
apoptosis of SW480 cells (Fig. 4B, C). R59949 promoted 
apoptosis to higher extent, independently of PP2 addition 
(Fig. 4C). Simultaneous addition of the two inhibitors, 
however, affected colony integrity as denoted by the 
decrease in the percentage of intact colonies (Fig. 4B and 
S6A).
Resistance to Src inhibition has been also attributed 
to the presence of additional oncogenic mutations. Lack 
of the PTEN phosphatase, a frequent mutation in breast 
tumors, enhances Akt activation and phosphotyrosine 
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signaling, which diminishes the efficacy of drugs that 
block RTK or SFK [56]. As for SW480 cells, simultaneous 
treatment of the PTEN negative MDA-MB-468 cells 
with R59949 and PP2 reduced Src phosphorylation and 
Cyclin D3 levels (Fig. 4D). Different from that observed 
in SW480 cells, phosphotyrosine profiles did not decrease 
accordingly and even some proteins of high molecular 
weight showed increased phosphorylation (Fig. 4D). PP2 
treatment promoted apoptosis of MDA-MB-468 cells 
grown in matrigel, although, as for SW480 cells, cell death 
increased if cells were treated with R59949 (Fig. 4E, F). 
Combination of PP2 with R59949 significantly increased 
apoptosis compared to individual treatments (Fig. 4F), and 
also increased the number of colonies with a disintegrated 
Figure 4: Blocking DGKα augments the sensitivity of cancer cells to Src inhibition. (A) SW480 cells cultured on 2D 
conditions were treated with the DGK inhibitor (20 µM), the indicated doses of PP2, or both (24 h). Active Src, phosphotyrosine profiles 
and cyclin D3 levels were analyzed by western blot. Actin was used as loading control. (B) SW480 cells were seeded on matrigel (4 days), 
and treated with inhibitors (48 h). Cells were fixed and apoptosis evaluated as cleaved caspase 3 staining. Actin and DAPI staining were also 
performed. (C) The number of caspase positive colonies was determined by examining several fields. The mean ± SEM of the percentage 
obtained for each group in different experiments is shown. (D-F) The PTEN-negative cell line MDA-MB-468 was treated with indicated 
drugs and analyzed as in A, B or C, respectively. Representative blots and fields are shown (n ≥3 independent experiments). Bar = 50 µm.
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integrity pattern (Fig. S6B).
Contrary to their previous effects, either individual 
or combined addition of R59949 and PP2 did not affect 
spheroid formation when added to 3D cultures of Caco-
2 or MCF-10A cells (Fig. S7). Our data concur with 
previous studies showing the synergistic effect of PP2 
with other inhibitors acting on the Src pathway in cancer 
cells, as has been recently described for PKCα inhibitors 
in breast cancer [57]. These findings strongly suggest that 
DGKα targeting could render cancer cells sensitive to Src 
inhibitors.
DGKα participates in the adaptive response of 
cancer cells to PI3K/Akt inhibition
DGKα gene expression is strictly controlled by 
FoxO factors; they promote transcriptional activity by 
binding to the DGKα distal region [14]. Akt-mediated 
phosphorylation of FoxO factors leads to their nuclear 
Figure 5: DGKα expression increases after PI3K inhibition. (A) SW480 cells were treated with Akt or PI3K inhibitors for the 
times indicated. Active Src, phosphotyrosine profiles and DGKα levels were analyzed by western blot. Phosphorylation of rpS6 was used 
as control of the inhibition. Tubulin was used as loading control. pSrc was normalized to Src expression. DGKα and prpS6 levels were 
normalized to those of tubulin. (B) SW480 cells were cultured in 2D or in 3D. LY294002 was added to the 3D culture (48 h). RNA was 
extracted and DGKα analyzed by qPCR. Expression was normalized to that of GAPDH. Mean ± SEM, n = 3. (C) SW480 cells were plated 
on matrigel and treated with R59949, LY294002, or both (48 h). Cells were fixed and stained for actin and caspase 3 and with DAPI. (D) 
The number of caspase positive colonies was determined by examining several fields from different experiments. The mean ± SEM of the 
percentage obtained for each group in different experiments is shown. (E-G) MDA-MB-468 cells were treated as in A, C or D. In A and E 
representative blots are shown (n =3 independent experiments). In C and F representative fields are shown (n ≥3 independent experiments). 
Bar = 50 µm.
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exit, which blocks their transactivatory function [58]. 
DGKα function thus lies downstream of the PI3K/Akt 
pathway and its function is expected be coupled to the 
cell differentiation programs controlled by FoxO family. 
Accordingly, DGKα expression in cytotoxic T populations 
is repressed by activation of the PI3K/Akt pathway [14]. 
FoxO factors also control expression of several receptor 
and non-receptor tyrosine kinases. Noteworthy, cancer 
cells rely on this mechanism to trigger tyrosine kinase 
signaling when PI3K or Akt inhibitors are used, which 
makes them resistant to the deleterious effects of these 
drugs [59, 60]. 
We tested whether PI3K/Akt inhibition in SW480 
colon cancer cells triggered activation of Src and tyrosine 
signaling, and if this correlated with transcriptional 
upregulation of DGKα. PI3K or Akt-inhibited cell cultures 
of SW480 cell showed increases in Src activation and in 
total phosphotyrosine profiles (Fig. 5A). DGKα protein 
levels increased after 24 h of treatment, a time in which Src 
activation reached the maximum grade (Fig. 5A). Since in 
3D culture conditions the expression of DGKα was higher 
than in 2D, we next determined its levels in this condition 
after PI3K inhibition. qPCR analysis of DGKα mRNA 
levels in PI3K/Akt-inhibited 3D cell cultures of SW480 
cells showed a 3- to 5-fold increase in DGKα expression 
relative to controls (Fig. 5B). By sustaining Src activation, 
increased DGKα levels might limit the deleterious effect 
of PI3K/Akt inhibitors on tumor survival. In agreement, 
combined inhibition of DGK and PI3K diminished 
cell growth and increased apoptosis more effectively 
than PI3K inhibition alone (Fig. 5C, D). The combined 
treatment also led to higher disruption of colony integrity 
compared to any of the single treatments (Fig. S6A).
Increases in Src activation and DGKα protein 
levels were also observed after PI3K/Akt inhibition in 
MDA-MB-468 cells (Fig. 5E). In these cells the effects 
were stronger when the PI3K inhibitor was used instead 
of the Akt inhibitor, probably due to the lack of PTEN. 
Changes on Src activation where not reflected in these 
cells in the total phosphotyrosine profile, differently from 
that observed in SW480 cells. In 3D culture conditions, 
PI3K inhibition promoted apoptosis at similar extent that 
R59949 (Fig. 5F, G), although the combined inhibition 
of DGK and PI3K increased the number of colonies with 
disintegrated structure (Fig. S6B). Inhibitors treatment did 
not affect spheroid formation by Caco-2 or MCF-10A cells 
when added either alone or in combination (Fig. S7).
Together these data suggest that the crosstalk 
between the PI3K/Akt/FoxO and Src pathways via DGKα 
provides cancer cells with a mechanism to adapt and 
subvert the deleterious effects of PI3K/Akt inhibition. 
DGKα targeting might therefore represent a useful and 
non-explored approach to combine with and prevent 
resistance to anti-cancer therapies aimed to inhibit the 
PI3K/AKT axis.
DISCUSSION
Improvement of anticancer therapies requires 
reliable identification of targets with a clear role in cancer 
cell adaptation to the cues of the tumor microenvironment. 
Three-dimensional cell culture constitutes a valuable tool 
for target identification, since it resembles the conditions 
that cells might encounter in vivo [61]. Compared to 2D, 
3D-cultured cells show patent differences not only in 
morphology, but also in the expression of various receptors 
and oncogenes, and in the response to drugs [62]. Here we 
identify DGKα upregulation as part of the reprogramming 
that occurs when breast and colon cancer cells grow in 
a 3D microenvironment. In addition, we demonstrate 
that DGKα silencing or its pharmacological targeting 
limits cell growth only when cells are 3D-cultured or 
xenografted in immune-compromised mice, but not 
during 2D cultures. Our data reinforce previous reports 
supporting a positive function of DGKα in cancer, and 
also provide a mechanistic link by showing that DGKα 
contributes to Src activation. These findings identify 
DGKα as a component of a positive feedback loop that 
contributes to Src-regulated functions and as a potential 
target for the development of anti-tumor therapies
Several reports indicate that DGKα sustains survival 
of cancer cells, including lymphoma, melanoma and 
hepatoma [2-4]. DGKα phosphorylation by Src correlates 
with the activation of its lipid kinase activity [17, 18], 
leading to PA generation. In this study we demonstrate 
that DGKα, in addition to its previous identification as a 
Src target, may also contribute to enhance Src functions. 
The mechanisms that control Src hyperactivation in cancer 
remain unclear [30] although it is becoming apparent 
that oncogenic Src functions are largely dictated by 
protein interactions that facilitate/restrict its activation. 
These modulators include upstream RTK, kinases and 
phosphatases that regulate Src conformation, as well 
as substrates that unclamp closed/inactive Src and lead 
to an open/active state [20, 63-65]. Additionally, Src 
activity is conditioned by its spatial localization or 
compartmentalization in distinct membrane microdomains 
[66, 67]. The unique features of DGKα might allow it to 
modulate Src at several levels, and thus contribute to its 
oncogenic properties.
The correlation between DGKα expression and 
Src autophosphorylation at Y419 correlates with the 
well-established mechanism of Src activation as a 
result of substrate interaction. Src modular structure 
facilitates activation by its substrates through a sequential 
mechanism: Src SH3 domain mediates the recognition of 
targets that contain proline-rich sequences. Subsequent 
phosphorylation leads to exposure of an additional Src 
docking site, generally a SH2 binding motif, promoting 
an open/active conformation of the kinase [21, 68]. DGKα 
does not have a consensus SH3 interaction motif, but its 
C-terminal region contains a proline stretch that interacts 
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with Src in vitro. This interaction drives subsequent 
phosphorylation of DGKα at Y335 providing additional 
anchorage to Src SH2 motif [18]. Our studies suggest that 
DGKα, like FAK and CAS, might belong to the family 
of Src substrates with capacity to promote Src activation.
The capacity of DGKα to trigger Src activation by 
means of interaction would be independent of its function 
as a PA producer. In agreement, we show that a kinase 
inactive DGKα was still capable to bind Src and become 
phosphorylated. Nonetheless, reconstitution experiments 
strongly suggest that DGKα activity contributes to Src 
activation. In this regard, recent studies have identified 
motifs for binding of acid lipids, including PA, in the Src 
unique and SH3 domains [69]. PA binding to Src would 
thus represent an additional layer of regulation to modify 
Src conformation and activity. In addition to PA mediated 
Src regulation, others have shown that DGKα-generated 
PA contributes to the survival and invasive properties 
of cancer cells by several mechanisms. DGKα-derived 
PA promotes mobilization and membrane tethering of 
RCP, a modulator of Rab protein trafficking, which is 
necessary for integrin recycling and cell migration in p53-
mutant background [7]. DGKα-PA production activates 
phosphodiesterase activity, that controls cAMP levels 
and the expression of cAMP responsive genes critical for 
cancer cell survival including mTOR and HIF-1 [11].
Our results suggest a model in which DGKα 
interaction with Src would allow mutual regulation of 
both kinases in a complex, multilayered process that 
would enhance PA production and Src activation. A 
partial contribution of DGKα-catalytic activity may help 
to explain the stronger effects on 3D growth observed 
following treatment with a pharmacological inhibitor 
when compared to those obtained after DGKα silencing. 
Whereas both treatments decrease total DGK activity to 
a similar extent, we demonstrate that R59949 treatment 
also promotes disruption of the DGKα-Src complex, most 
probably as a consequence of steric interference. A partial 
DGKα depletion following genetic silencing (aprox. 60% 
of total enzyme) would be less effective than the inhibitor 
targeting complex formation. 
This role for DGKα as a Src modulator helps to 
understand the stronger addiction for this lipid kinase 
of transformed cells when growing in 3D compared to 
non-transformed, acini forming cells. This is likely the 
consequence of the strict requirement that transformed 
cells have for Src-mediated regulation of growth and 
survival pathways in the context of matrix components. 
It also explains the apparent lack of effect when cells are 
grown in 2D cultures.
DGKα promotion of Src activation might also 
explain the higher DGKα levels found in hepatic tumors 
when compared to untransformed neighboring tissue 
[4]. DGKα is increased in 20% of hepatomas, where it 
is associated with high Ki67 levels and recurrence rate. 
In these studies, the authors suggest that DGKα promotes 
MEK/ERK activation by a Ras-independent mechanism. 
It is tempting to suggest a function for DGKα promoting 
Src signaling in this cancer type, since there is mounting 
evidence of a role for Src in hepatocellular carcinoma 
development [70].
Our studies define an important contribution 
of DGKα to Src mediated functions. The increased 
DGKα expression observed at distinct stages of cancer 
progression, that is, from initial to metastatic growth 
[13] correlates with the reported function of Src in 
metastasis and suggests DGKα upregulation in response 
to stress conditions, such as limited nutrient availability 
or chemotherapy treatments. In this latter case, our 
data demonstrate that DGKα expression, upregulated 
in response to PI3K/Akt inhibition, contributes to Src 
activation, and provide additional proof of DGKα as 
part of tumor escape mechanisms. In summary, DGKα 
upregulation in 3D context links the function of this 
enzyme to tumor survival and drug resistance mechanisms, 
and further supports development of new drug therapies 
based on this lipid kinase.
MATERIALS AND METHODS
Cell lines and culture
MCF-10A, HEK293 and SW480 cells were 
purchased from the ATCC. MDA-MB-468 was kindly 
donated by Dr. L. Planelles (CNB/CSIC) and Caco-2 
by Dr. A. González (CNB/CSIC). SW480 cells were 
maintained in DMEM (Lonza) supplemented with 10% 
FBS (GBio) and 2 mM L-Gln (Gibco). Caco-2 cells were 
maintained with 1 mM sodium pyruvate (Gibco). MCF-
10A cells were maintained in DMEM/F12 (Lonza, 1:1, 
v/v), 5% horse serum (Gibco), 2 mM L-Gln, insulin-
transferrin-selenium (Gibco), 500 ng/ml hydrocortisone 
(Calbiochem) and 20 ng/mL epidermal growth factor 
(EGF, Upstate). MDA-MB-468 cells were cultured in 
Leibovitz’s medium (L15, Lonza). All cell lines were 
maintained at 37ºC and 5% CO2 except MDA-MB-468, 
which was cultured without CO2 in L15 medium. Identity 
of the breast-derived cell lines was confirmed by STR 
genotyping (Genomics Facility, IIB/CSIC, Madrid, Spain).
Antibodies and reagents
Antibodies to p-Src Y416, Src (clones 36D10 and 
L4A1), p-rpS6 S240/4, cyclin D3, cleaved-caspase 3 
and myc-tag (clone 9B11) were purchased from Cell 
Signaling. Anti-DGKα was from Abnova, monoclonal 
anti-β-actin and -α-tubulin antibody from Sigma-Aldrich, 
and anti-GAPDH from Santa Cruz Biotechnology. Anti-
phosphotyrosine (4G10) was from Upstate.
Leupeptin and aprotinin were from Roche, growth 
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factor reduced-matrigel from BD Biosciences. R59949 
(DGK inhibitor II; 3-{2-(4-[bis-(4-fluorophenyl)
methylene]-1-piperidinyl)ethyl}-2,3-dihydro-2-thioxo-
4(1H)quinazolinone), PP2, LY294002 and Akt Inhibitor 
VIII (Akti) were from Calbiochem. All other reagents 
were from Sigma-Aldrich.
DGK silencing
DGK-targeting was performed using the human 
DGKα (nt 1153-1173) and DGKζ (nt 2290-2310) 
validated sequences [35, 36, 71]. For transient silencing 
the sequences were transfected as dsRNA (Ambion) 
using oligofectamine (Invitrogen). A scramble dsRNA 
was used as control (Ambion). Effective DGK depletion 
was achieved at 72-96 h post-transfection. After 96h 
the expression was recovered. For stable silencing, 
64 pb double strand oligonucleotides, encompassing 
the corresponding interfering 21 nt sequence and a 
hairpin structure, were cloned in the pSuperRetro vector 
(Oligoengine). As control the pSuperRetro construct 
harboring the homolog specific DGKζ mouse sequence 
was used. This control did not reduce the levels of human 
DGKα or ζ. SW480 cells were infected using standard 
protocols with the pSuperRetro-cloned sequence-
containing retroviruses. Cells with the retrovirus insertion 
were selected by culturing in media with G418 (800 µg/
ml) until the control, non-infected cells died (∼1 week). 
The pools were checked for DGK silencing, maintained in 
media with G418 (500 µg/ml) and used in the long-term 
experiments.
Cell drug treatments
The different inhibitors were added to plated cells 
in complete media for the indicated time (24 to 48 h). 
For DGK inhibition the DGK inhibitor II (R59949) was 
used since this drug has been reported by our laboratory 
and others to be much more potent and specific that DGK 
inhibitor I [38, 47]. To avoid inactivation of R59949 by the 
serum present in the culture medium and/or the long times 
of treatment, inhibitor  doses from 15 to 30 µM in DMSO 
were used in the experiments.
DGK assays
DGK activity was measured using 1,2-dioleoyl 
(C18:1)-DAG as substrate. Lipid micelles containing 
the substrate were prepared by sonication of the lipid in 
the presence of PtdSer (10 min, room temperature (RT)); 
the final concentration of both lipids in the assay was 2 
mM. Cells were lysed by sonication in Tris-HCl 50 mM 
pH 7.5, with protease and phosphatase inhibitors (20µM 
leupeptin, 1.5µM aprotinin, 1mM PMSF, 2mM sodium 
fluoride, 40mM β-glycerolphosphate and 1mM sodium 
orthovanadate). Cell lysates were centrifuged (12000 x g, 
15 min, 4ºC), and 20 µg of the resulting supernatant mixed 
with lipid micelles containing the substrate. The reaction 
was initiated by addition of reaction mix (1 mM ATP, 10 
mM MgCl2, 100 mM NaCl, 1 mM DTT and 10 µCi [γ-
32P]
ATP) and incubated (10 min, 25ºC) in a final volume of 
50 µl, and was terminated by addition of 1 N HCl. Lipids 
were extracted after addition of CHCl3/MeOH (2:1 v/v). 
The organic layer was recovered, dried and applied to 
silica gel TLC plates, which were developed in a CHCl3/
MeOH/4 M NH4OH solvent system (9:7:2 v/v/v), dried, 
and autoradiographed. A non-radioactive standard of the 
reaction product was used to identify the lipid of interest.
Cell Proliferation
The effect of the distinct drugs over cell proliferation 
was determined by evaluating the cell viability using the 
Promega Cell Titer cell proliferaton assay and according 
to the manufacturer instructions. The cells were cultured in 
96 well plates in either 2D or 3D conditions. Absorbance 
was measured at 492 nm in a Sunrise Tecan instrument.
Expression vectors and transfection
Myc-DGKα cloned in pMT2 was a kind gift of Dr. 
A. Graziani (University of Piamonte Orientale, Italy). 
A kinase-dead version of the enzyme was generated, 
Gly 434 to Ala, using the Quick-Change mutagenesis 
kit. Oligonucleotides used were: DGKA-G434Aforw: 
5´-TTGCTGTGTGGTGCAGACGGCACAGTA-3´, 
DGKA-G434Arev:5´-TACTGTGCCGCTTGCACCACA 
CACCAA-3´. Nucleotides underlined encoded for the 
modified amino acid.
The plasmid encoding Src was generated by cloning 
chicken Src into pCDNA3. Transfections were performed 
with Lipofectamine LTX/Plus reagent (Invitrogen).
Western blot
For lysates, cells were washed in cold PBS, and 
scraped into ice-cold lysis buffer (50 mM Hepes pH 7.4, 
150 mM NaCl, 1% TritonX-100, 10% glycerol) with 
protease and phosphatase inhibitors (20 µM leupeptin, 1.5 
µM aprotinin, 1 mM PMSF, 1 mM sodium orthovanadate, 
40 mM β-glycerophosphate, 2 mM NaF). Clarified 
lysates were quantified with the Pierce 660 nm Protein 
Assay (Thermo Scientific), denatured in Laemmli buffer, 
and resolved by PAGE. Proteins were transferred to 
nitrocellulose membranes (Bio-Rad) and incubated with 
the indicated antibodies.
To prepare lysates from matrigel, cell cultures 
were scraped into PBS with 5 mM EDTA, protease and 
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phosphatase inhibitors, and matrigel allowed to liquefy 
(30 min, 4ºC). Cells were centrifuged (2000 xg, 5 min, 
4ºC), washed twice in PBS with 5 mM EDTA and 
processed as above.
Immunoprecipitation
For protein-protein interaction analysis, cells were 
lysed (30 min, 4ºC) as above. Lysates (500 µg-1 mg) were 
incubated (overnight, 4ºC) with appropriate antibody, 
followed by 50 µl 50% protein G-Sepharose slurry (1 
h, 4ºC). Immunoprecipitates were washed thrice in lysis 
buffer and once with 0.5 M LiCl. Immunoprecipitated 
proteins were resolved by SDS-PAGE and transferred to 
nitrocellulose membranes for Western blot analysis.
3D cell culture
3D cell culture on matrigel was performed as 
described [46]. Briefly, 300 µl matrigel was added 
to each well of a 6-well chamber (10 cm2 surface) and 
allowed to solidify (20 min, 37ºC). Cells were trypsinized, 
resuspended in assay medium (normal medium with 2.5% 
matrigel) and seeded (1.5 to 3 x 103 cells/cm2). Assay 
medium was changed every 48 h, and cells allowed 
to grow up to 14 days. For inhibitor treatment, cells 
were allowed to grow for 4 days, and then treated for 2 
additional days.
Colony formation assays
Cells (5 x 102/well) were seeded in 12-well plates 
and allowed to grow for 10 days. Colonies and foci were 
stained with 0.1% crystal violet solution in 20% methanol. 
After extensive washing, crystal violet was dissolved in 
10% acetic acid, and absorbance measured at 620 nm in a 
Sunrise Tecan instrument.
Immunofluorescence
Cells were plated on matrigel-coated (60-70 µl) 
8-well chambers (Ibidi) and after treatment as indicated, 
were fixed in 4% paraformaldehyde (10 min, RT). Cells 
were permeabilized with 0.5% Triton X-100 (30 min), 
blocked with 10% goat serum, 0.05% TritonX-100 in 
TBS (30 min, 37ºC), and incubated with appropriate 
primary antibody in incubation buffer (1% goat serum 
in TBS; 3 h, 37ºC) in a humidified chamber. Secondary 
antibodies (goat anti-rabbit Alexa Fluor 488 or 594; both 
from Invitrogen) were added and incubated (1 h, RT). To 
assess proliferation, EdU (Click-iT EdU Cell Proliferation 
Assays, Life Technologies) was used as recommended. 
Finally, samples were incubated with DAPI (Invitrogen, 
1:1000, 20 min, RT) and Alexa Fluor 488- or TRITC-
conjugated phalloidin (Invitrogen, 1:1000, 20 min, RT), 
mounted in PBS:glycerol (1:1, v/v), and visualized under 
a Leica TCS SP5 confocal microscope.
Real time PCR
RNA was extracted from cell cultures using Trizol 
reagent (Invitrogen). cDNA was synthesized from cell 
culture-extracted RNA (1 µg) after DNase (Invitrogen) 
treatment and retrotranscription with Random Primers 
(Applied Biosystems) and SuperScript II Reverse 
Transcriptase (Invitrogen). qPCR reactions were 
performed with the Power SYBR Green PCR Master 
Mix (Applied Biosystems) in 10 µl final volume. PCR 
conditions were as follows: 50ºC (10 min), 95ºC (2 min), 
40 cycles at 95ºC (15 s) and 60ºC (1 min). Reactions 
were run in triplicate with the Applied Biosystems 
7900HT system. Relative expression of each gene was 
calculated using the ∆∆Ct method. GAPDH was used 
as control. Oligonucleotides used were: DGKAforw: 
5´-CAATCACATCTGTGGGTGCGAGGA-3´, 
DGKArev: 5´-TTCCCGCCACTCTTAGGATTGAC-3´; 
GAPDHforw: 5´-ACAGCCTCAAGATCATCAGCAA-3´, 
GAPDHrev: 5´-ATGGCATGGACTGTGGTCATG-3´.
Xenograft model
All mouse work was carried out in accordance with 
a protocol approved by the CNB/CSIC Ethics Committee 
for Animal Experimentation (CEEA-CNB, no. 090004). 
SW480-shRNA-control and -shRNA-DGKα cells (1.5 
x 106) were injected subcutaneously (s.c.) into the flank 
of female BALB/c SCID mice aged 6-8 weeks. Tumor 
growth was monitored every two days and volume 
estimated according to the formula: volume = (a2 x b)/2, 
where a = tumor width and b = tumor length in mm. At 
the end of the experiment (when control tumors reached 
1 cm3, ~30 days), mice were sacrificed, tumors extracted 
and weighed. 
To assay the effect of the DGK inhibitor R59949 
on in vivo tumor growth, SW480 parental cells (106) 
were injected s.c. into the flank of female mice as 
above. Pharmacological treatment was initiated when 
tumors reached ≥150 mm3 (~15 days). R59949 was 
administered s.c. (10 mg/kg) every 48 h for 10 days. The 
tumor volume and weight of each mouse was recorded 
along the treatment. Mice were sacrificed 48 h after 
the last dose. Tumors were weighed and then fixed 
overnight in paraformaldehyde, followed by dehydration 
in graded ethanol, and embedded in paraffin for 
immunohistochemical studies.
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Immunohistochemistry
Tissue sections were formalin-fixed and paraffin-
embedded. Sections were prepared for antibody staining 
as described [72]. Briefly, following deparaffinization and 
hydration, antigen retrieval was performed in 12.5 mM 
sodium citrate pH 6.0 (30 min, 90ºC). Tissue sections 
were washed in TBSt (TBS, 0.1% Tween-20) and blocked 
with 10% goat serum (1 h, room temperature). Primary 
antibody was incubated (overnight, 4ºC), followed by 
incubation with HRP-coupled secondary antibody (Dako, 
1:200, 2 h, room temperature). Staining was detected with 
the DAB Peroxidase Substrate Kit (Vector Laboratories), 
and slides were counterstained with hematoxylin (Fisher 
Scientific) and mounted in Permount (EMS).
Statistical analyses
Gel bands were quantified with ImageJ software 
(NIH). Student’s t-test was used to compare data. When 
variance was significantly different as analyzed with the 
F-test, Welch’s correction was applied. When samples did 
not fit normality as tested with the Kolmogorov-Smirnov 
test, the Mann-Whitney test was used. Statistical analysis 
was done with GraphPad Prism 5 software. When the 
p-value <0.05, differences were considered significant (* 
p<0.05; ** p<0.01; *** p<0.001).
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